Home › Compare › STSGF vs ABBV
STSGF yields 3.09% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, STSGF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of STSGF + ABBV for your $10,000?
STS Group AG is a supplier of components and systems for the commercial vehicle and automotive industry primarily in Germany, France, Mexico, and China. The company operates through three segments: Plastics, China, and Materials. It manufactures and sells interior systems and components, such as storage modules, including under bunk storage and upper shelf; exterior components comprising cab side modules, tailgates, rear lamp modules, and roof spoilers for trucks, commercial vehicles, and passenger cars; roof modules for trucks; and covers of battery system for electric vehicles. The company also offers plastic parts for the cabins for commercial vehicles, as well as bumpers, front panels, deflectors, roofs, fenders, and entrances; and develops and produces sheet molding compounds, fiber molding compounds, and advanced fiber molding compounds. In addition, it provides prototyping and logistics services. The company was founded in 2013 and is headquartered in Hagen, Germany. STS Group AG is a subsidiary of Adler Pelzer Holding GmbH.
Full STSGF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.